Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Eargo, Inc.    EAR

EARGO, INC.

(EAR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Eargo : to Announce Third Quarter 2020 Financial Results

11/09/2020 | 04:02pm EST

SAN JOSE, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Eargo Inc., (NASDAQ: EAR), a medical device company on a mission to improve the quality of life of people with hearing loss, today announced it will release financial results for the third quarter of 2020 after market close on Thursday, November 19, 2020. On the same day, Eargo will host a conference call and webcast at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to discuss its financial results and recent highlights.

Interested parties may access the live call via telephone by dialing (833) 649-1234 for domestic callers or (914) 987-7293 for international callers, using conference ID: 2826509. The live webinar of the call may also be accessed by visiting the Events and Presentations section of Eargo’s website at ir.eargo.com. A replay of the webinar will be available shortly after the conclusion of the call and will be archived on Eargo’s website.

About Eargo
Eargo is a medical device company dedicated to improving the quality of life of people with hearing loss. Our innovative product and go-to-market approach address the major challenges of traditional hearing aid adoption, including social stigma, accessibility, and cost. We believe our Eargo hearing aids are the first and only virtually invisible, rechargeable, completely-in-canal, FDA regulated, exempt Class I device for the treatment of hearing loss. Our differentiated, consumer-first solution empowers consumers to take control of their hearing. Consumers can purchase online or over the phone and get personalized and convenient consultation and support from licensed hearing professionals via phone, text, email, or video chat. The Eargo solution is offered to consumers at approximately half the cost of competing hearing aids purchased through traditional channels in the United States.

The company’s 4th generation product, the Eargo Neo HiFi, was launched in January and features improved capabilities across audio fidelity and bandwidth. The Eargo Neo HiFi is available for purchase here.

Investor Contact
Nick Laudico
Vice President of Investor Relations
ir@eargo.com

Media Contact
Aaron Murphy
eargo@edelman.com


Main Orange.png

Source: Eargo

2020 GlobeNewswire, Inc., source Press Releases

All news about EARGO, INC.
01/26EARGO : Ally Lending teams with Eargo to empower those with hearing loss
PR
01/11EARGO : Q4 Preliminary Revenue Surpasses Street Estimates -- Stock Rises Over 3%..
MT
01/11EARGO, INC. : Results of Operations and Financial Condition, Financial Statement..
AQ
01/11Eargo Announces Preliminary Unaudited Fourth Quarter and Full Year 2020 Net R..
GL
2020Eargo to Present at 39th Annual J.P. Morgan Healthcare Conference
GL
2020Eargo Ranks First for Best Company Culture in Comparably Awards
GL
2020EARGO : Management's Discussion and Analysis of Financial Condition and Results ..
AQ
2020EARGO, INC. : Results of Operations and Financial Condition, Financial Statement..
AQ
2020Earnings Flash (EAR) EARGO Reports Q3 Revenue $18.2M
MT
2020EARGO : Reports Third Quarter 2020 Financial Results
AQ
More news
Financials (USD)
Sales 2020 66,8 M - -
Net income 2020 -38,0 M - -
Net cash 2020 196 M - -
P/E ratio 2020 -114x
Yield 2020 -
Capitalization 2 177 M 2 177 M -
EV / Sales 2020 29,7x
EV / Sales 2021 23,2x
Nbr of Employees 214
Free-Float 98,9%
Chart EARGO, INC.
Duration : Period :
Eargo, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EARGO, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 57,00 $
Last Close Price 57,01 $
Spread / Highest target 22,8%
Spread / Average Target -0,02%
Spread / Lowest Target -28,1%
EPS Revisions
Managers and Directors
NameTitle
Christian Gormsen President, Chief Executive Officer & Director
Raphael Michel Chairman & Chief Strategy Officer
William Brownie Chief Operating Officer
Adam Laponis Chief Financial Officer
Daniel Shen Chief Clinical & Science Officer
Sector and Competitors
1st jan.Capitalization (M$)
EARGO, INC.27.20%2 177
THERMO FISHER SCIENTIFIC9.03%201 271
DANAHER CORPORATION0.03%166 214
INTUITIVE SURGICAL, INC.-7.26%90 477
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.14.55%85 238
ILLUMINA, INC.16.84%61 400